桂枝茯苓胶囊联合曲美他嗪治疗痰淤交阻型冠心病心绞痛患者临床研究

Clinical Study of Guizhi Fuling Capsule Combined with Trimetazidine in the Treatment of Angina Pectoris of Coronary Heart Disease with Phlegm Stasis Obstruction

目的进行桂枝茯苓胶囊联合曲美他嗪治疗痰淤交阻型冠心病心绞痛患者临床研究。方法选取2018年8月至2019年8月收治的150例痰淤交阻型冠心病心绞痛患者,随机将其分为对照组和观察组,各75例,对照组患者予以阿司匹林、β受体阻滞剂等常规治疗及曲美他嗪治疗,观察组患者在同等常规治疗的基础上采用曲美他嗪联合桂枝茯苓胶囊治疗,分别观察两组临床治疗疗效、治疗前后血脂水平变化、心功能变化、不良反应发生率及心绞痛发作次数、持续时间及硝酸甘油使用量。结果与对照组临床总有效率(64.00%)比较,观察组临床总有效率(90.66%)更显著(P<0.05);两组治疗后TC、TG、LDL-C均低于治疗前(P<0.05),且观察组TC、TG、LDL-C下降幅度大于对照组(P<0.05);治疗后两组LVEF、SV均有升高,且观察组上升幅度大于对照组(P<0.05),LVEDD、LVESD均有所降低,且观察组下降幅度大于对照组(P<0.05);治疗后两组心绞痛发作次数、持续时间及硝酸甘油使用量均有所减少,且观察组减少幅度大于对照组(P<0.05);对照组不良反应发生率为12.00%,显著高于观察组(5.33%,P<0.05)。结论桂枝茯苓胶囊联合曲美他嗪治疗痰淤交阻型冠心病心绞痛患者显著提高了其临床治疗疗效,有效改善了心功能及血脂水平,临床应用价值较高。

Objective To compare and study the clinical study of Guizhi Fuling Capsule combined with trimetazidine in the treatment of angina pectoris of coronary heart disease with phlegm stasis obstruction.Methods 150 patients with coronary heart disease and angina pectoris of phlegm stasis type treated from August 2018 to August 2019 were randomly divided into control group and observation group,with 75 cases in each group.The patients in the control group were given aspirinβThe patients in the observation group were treated with trimetazidine combined with Guizhi Fuling Capsule on the basis of the same routine treatment.The clinical curative effect,the changes of blood lipid level,cardiac function,the incidence of adverse reactions,the number and duration of angina pectoris and the dosage of nitroglycerin were observed.Results Compared with 64.00%in the control group,90.66%in the observation group was more significant(P<0.05);After treatment,TC,TG and LDL-C in the two groups were lower than those before treatment(P<0.05),and the decrease range of TC,TG and LDL-C in the observation group was greater than that in the control group(P<0.05);After treatment,LVEF and SV increased in both groups,and the increase range in the observation group was greater than that in the control group(P<0.05),LVEDd and LVESD decreased,and the decrease range in the observation group was greater than that in the control group(P<0.05);After treatment,the number and duration of angina pectoris and the use of nitroglycerin in the two groups decreased,and the decrease in the observation group was greater than that in the control group(P<0.05);The incidence of adverse reactions in the control group was 12.00%,which was significantly higher than 5.33%in the observation group(P<0.05).Conclusion Guizhi Fuling Capsule Combined with trimetazidine in the treatment of patients with angina pectoris of coronary heart disease with phlegm and stasis obstruction significantly improved its clinical therapeutic effect,effectively improved cardiac function and blood lipid level,with definite effect and high clinical application value.